RT Journal Article
SR Electronic
T1 Containment of a multi-index B.1.1.7 outbreak on a university campus through a genomically-informed public health response
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.04.22268758
DO 10.1101/2022.01.04.22268758
A1 Martin, Emily T.
A1 Lauring, Adam S.
A1 Montgomery, JoLynn P.
A1 Valesano, Andrew L.
A1 Eisenberg, Marisa C.
A1 Sheen, Danielle
A1 Nord, Jennifer
A1 Ernst, Robert D.
A1 Mortenson, Lindsey Y.
A1 Valdez, Riccardo
A1 Niknafs, Yashar
A1 Conway, Darryl
A1 Rifat, Sami F.
A1 Bagdasarian, Natasha
A1 Lyon-Callo, Sarah
A1 Collins, Jim
A1 Blankenship, Heather
A1 Soehnlen, Marty
A1 Marquez, Juan
YR 2022
UL http://medrxiv.org/content/early/2022/01/05/2022.01.04.22268758.abstract
AB The first cluster of SARS-CoV-2 cases with lineage B.1.1.7 in the state of Michigan was identified through intensive university-led surveillance sampling and targeted sequencing. A collaborative investigation and response was conducted by the local and state health departments, and the campus and athletic medicine COVID-19 response teams, using S-gene target failure screening and rapid genomic sequencing to inform containment strategies. A total of 50 cases of B.1.1.7-lineage SARS-CoV-2 were identified in this outbreak, which was due to three coincident introductions of B.1.1.7-lineage SARS-CoV-2, all of which were genetically distinct from lineages which later circulated in the broader community. This investigation demonstrates the successful implementation of a genomically-informed outbreak response which can be extended to university campuses and other settings at high risk for rapid emergence of new variants.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: Financial support for the submitted work from CDC and from university COVID response funds. E.T.M. has received grant funding from CDC, NIH, and Merck. A.S.L. has received grant funding from CDC, NIH, and Burroughs Wellcome Fund and consulting fees from Sanofi and Roche. Y.N. is co-owner of LynxDx, Inc. D.C. has received speaker fees from National Athletic Trainers' Association, Far West Athletic Trainers' Association, and Tenessee Athletic Trainers' Society and consulting fees from The Rehberg-Konin GroupFunding StatementSequencing was supported by CDC contract 75D30120C09870 (to ASL) and University COVID response funds.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Michigan Institutional Review BoardI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors if approved by the Insitutional Review Boards of participating insitutions.